Clinical Trials in China / NCT07189455
Recruiting
Phase 3
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
NCT07189455 · tracked via the Priya Life Science China tracker
Condition(s) studied
Small-cell Lung Cancer
Investigational drug(s) / intervention(s)
ZG006: ZG006 will be administered as an intravenous (IV) infusion.
Topotecan: Topotecan will be administered per local standard of care
Study summary
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Eligibility
Inclusion Criteria:
* Fully understand the study and voluntarily sign the informed consent form;
* Male or female 18\~75 years of age;
* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
* Life expectancy ≥ 3 months;
* Histologically or cytologically confirmed Small Cell Lung Cancer.
Exclusion Criteria:
* Participants were deemed unsuitable for participating in the study by the investigator for any reason.
Primary outcome measure(s)
- Overall Survival (OS) — Up to approximately 3 years
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Shanghai Chest Hospital | Shanghai | Shanghai Municipality | Recruiting |
More Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials in China
Other trials for the same condition
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07189455 on ClinicalTrials.gov ↗ ← All trials in China